Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 11:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 959 matching trials from the live ClinicalTrials.gov search.
Conditions
Glioblastoma
Interventions
TH-1 Dendritic Cell Immunotherapy
Biological
Lead sponsor
Cooper Norcross Health
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Camden, New Jersey • Houston, Texas
Conditions
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions
Idarubicin, Cytarabine, Lenalidomide (Revlimid®)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
2
States / cities
Tampa, Florida • Cleveland, Ohio
Conditions
Solid Tumor
Interventions
JBZ-001
Drug
Lead sponsor
Jabez Bioscience, Inc
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Columbus, Ohio • West Valley City, Utah
Conditions
Advanced Cancer
Interventions
SGX523 Capsules
Drug
Lead sponsor
SGX Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Santa Monica, California • Nashville, Tennessee
Conditions
Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions
Valproate, Placebo, Patch
Drug · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
Interventions
LTZ-301
Biological
Lead sponsor
LTZ Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Duarte, California • St Louis, Missouri • Buffalo, New York + 3 more
Conditions
Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer
Interventions
ECT204 T cells
Biological
Lead sponsor
Eureka Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Duarte, California • Westwood, Kansas • Buffalo, New York + 4 more
Conditions
Breast Cancer
Interventions
Intraductal arm, Intravenous arm
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Conditions
Corona Virus Infection
Interventions
Zotatifin, Placebo
Drug
Lead sponsor
Effector Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Tampa, Florida + 1 more
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
revumenib, cobicistat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
30 Days and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 17 more
Conditions
CML, AML, MDS, ALL, NHL, Multiple Myeloma, Hodgkin's Disease
Interventions
Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells, Observation Arm
Biological · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Lymphoma
Interventions
plasmid DNA vaccine therapy, flow cytometry, immunoenzyme technique
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
ProAgio Dose Levels (DL) 1,2,3,4, Gemcitabine, nab paclitaxel
Drug
Lead sponsor
ProDa BioTech, LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
Interventions
MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole
Drug
Lead sponsor
Metagen Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Naples, Florida • Boston, Massachusetts • New York, New York
Conditions
Neoplasms by Site
Interventions
Denenicokin, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Tampa, Florida + 2 more
Conditions
Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Interventions
vorinostat, cisplatin, radiation therapy, Correlative Studies
Drug · Radiation · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Obesity
Interventions
Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Interventions
IMGN151, Carboplatin, Bevacizumab, Olaparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Minneapolis, Minnesota + 10 more
Conditions
COVID-19 Infection
Interventions
Placebo Administration, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1
Drug · Biological
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Claremont, California • Duarte, California • Thousand Oaks, California
Completed Phase 1Phase 2 Interventional Results available

RTA 408 Capsules in Patients With Melanoma - REVEAL

NCT02259231
Conditions
Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
Interventions
Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg), Omaveloxolone Capsules (10 mg/capsule), Omaveloxolone Capsules (50 mg/capsule)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
10
States / cities
Mobile, Alabama • Fayetteville, Arkansas • Aurora, Colorado + 7 more
Conditions
Cancer
Interventions
Paclitaxel, 5-Fluorouracil (5FU), Carboplatin, Leucovorin, Irinotecan, BMS-906024
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Cancers
Interventions
Crizotinib, Dasatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Solid Tumors
Interventions
clofarabine (oral formulation)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Dallas, Texas • Tyler, Texas • Spokane, Washington
Conditions
Neonatal Abstinence Syndrome
Interventions
Morphine, Methadone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
0 Hours to 12 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico